Wide Ranks

IMTXW

Immatics N.V.

0.4000

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth -16.10 %
Current Ratio 3.74 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -104.01 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins -104.01 % Operating Margins -141.64 %
Balance Sheet
Total Cash 158 M Total Cash Per Share 1.53 Total Debt 17 M
Total Debt To Equity 4.49 Current Ratio 3.74 Book Value Per Share 2.66
All Measures
Message Board Id finmb_8986547 Fax 49 7071 5397 900 Return On Equity -0.2432
City Tübingen Uuid 4acf50b5-d74d-3dfd-b98b-e771b84f667b Previous Close 0.4300
Book Value 2.66 Beta 0.7760 Total Debt 17 M
Volume 8832 Price To Book 0.1504 Fifty Two Week Low 0.4000
Total Cash Per Share 1.53 Total Revenue 70 M Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -141.64 % Net Income To Common -73713000
Trailing Peg Ratio None Total Cash 158 M Revenue Per Share 0.7660
Ebitda Margins -134.32 % Trailing PE 0.0000 Regular Market Previous Close 0.4300
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Open 0.4101
Free Cashflow -423208000 Dividend Yield 0.00 % Return On Assets -0.1217
Time Zone Short Name EST Day Low 0.4000 Address1 Paul-Ehrlich-Strasse 15
Target High Price 0.0000 Price Hint 4 Website https://www.immatics.com
Forward Eps 0.0000 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 108.20 % Is_sp_500 False Regular Market Day High 0.4101
Profit Margins -104.01 % Debt To Equity 4.49 Fifty Two Week High 0.4101
Day High 0.4101 Regular Market Open 0.4101 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth -16.10 % Operating Cashflow -17274000
Currency USD Time Zone Full Name America/New_York Is_nasdaq_100 False
Market Cap 0.0000 Zip 72076 Quote Type EQUITY
Industry Biotechnology Long Name Immatics N.V. Regular Market Day Low 0.4000
Current Price 0.4000 Financial Currency EUR Current Ratio 3.74
Gross Margins -87.72 % Industry Disp Biotechnology Country Germany
Float Shares 62 M Forward PE 0.0000 Regular Market Volume 8832
Ebitda -95191000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Immatics N.

V.

, a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.

The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.

The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial.

The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.

Immatics N.

V.

is headquartered in Tübingen, Germany.